Second transplant with twounrelatedcordbloodunitsforearlygraft failure after haemato poieticstemcell transplantation
ShortReport
TableI.DetailedcharacteristicsofpatientsreceivingadoublecordbloodtransplantationforearlygraftfailureafterapreviousHSCT.
Patient1
Characteristicsof rsttransplantsDiagnosis
Donortype
NumberofHLAmismatching(loci)ClassIClassII
Totalnucleatedcellsatinfusion/kg·107CD34+celldoseatinfusion/kg·105Conditioningregimen
Patient2
Patient3
Patient4
CMLUnrelatedBM1(C)011Æ594Æ6
Cy120mg/kgFTBI12Gy
SAASingleUCB
1(B)1(DRB1)3Æ32Æ3
Bu4,8mg/kgCy40mg/kgFlud90mg/m2ATG10mg/kgCsAMPNo
CMV,HHV-6
100%donor(D+39)37%donor(D+67)14812UCB2(A,B)
AML(FABM4)Monosomy7SingleUCB2(A,B)1(DRB1)2Æ31Æ5
Bu12,8mg/kgMel140mg/m2ATG10mg/kgCsAMPNo
ToxoplasmosisNANA28752UCB2(A,B)1(DRB1)2(A,B)1(DRB1)5,93,2
Cy35mg/kgFlud120mg/m2ATG5mg/kgCsA19/42
AML(FABM3)t(15;17)SingleUCB1(B)1(DRB1)1Æ90Æ84
Flud90mg/m2Mel140mg/m2
GVHDprophylaxisGVHDInfectionsChimaerism
Timebetweenthedecisionandthesecondtransplant(days)
Intervalbetweentransplants(days)56CharacteristicsofsecondtransplantsDonortype2UCBNumberofHLAmismatching(loci)( rstunit)ClassI1(B)ClassII
NumberofHLAmismatching(loci)(secondunit)ClassI1(B)ClassII
Totalnucleatedcellsatinfusion/kg·1073,1
+5
CD34celldoseatinfusion/kg·102,2ConditioningregimenCy35mg/kg
Flud90mg/m2ATG10mg/kg
GVHDprophylaxisCsA
9
Neutrophil(>0Æ5·10/l)andplatelets31/127
9
(>20·10/l)recovery(daysaftersecondtransplant)
Chimaerism( rstunit¼D1,secondunit¼D2)Day3080%D1,20%D2Day60100%D2Day100100%D2AcuteGVHDNoChronicGVHDExtensiveInfectiouscomplicationsPTLD(EBV),HSVSurvivalpostsecondtransplant25monthsStatusAlive
CsA
MethotrexateaGVHD(gradeI)No
76%donor(D+27)100%recipient(D+40)16CsAMMFNoCMV
100%recipient(D+12)100%recipient(D+61)14762UCB2(A,B)1(DRB1)1(B)1(DRB1)6,55,7
Cy50mg/kgFlud90mg/m2TBI2GyCsA+MMF15/NA
2(A,B)2,91,5
Cy50mg/kgFlud90mg/m2TBI2GyCsA27/112
NANA
100%D2
aGVHDgradeIILimited
RSV,CMV,VZV12monthsAliveNANA
100%D1
aGVHDgradeIIExtensiveCMV
12monthsAlive100%D1–-aGVHDgradeIV–
Adenovirus46daysDeceased
SAA,severeaplasticanemia;CML,chronicmyeloidleukemia;AML,acutemyeloidleukaemiaUCB,unrelateddonorcordblood;BM,bonemarrow;Bu,i.v.busulfan;Cy,cyclophosphamide;Flud, udarabine;FTBI,fractionatedtotalbodyirradiation;Mel,melphalan;ATG,anti-thymocyteglobulin;CsA,ciclosporinA;NA,notavailable;MMF,mycophenolatemofetil;MP,methylprednisoloneCMV,cytomegalovirus;VZV,varicellazostervirus;aGVHD,acutegraft-versus-hostdisease;cGVHD,chronicgraft-versus-hostdisease;RSV,respiratorysyncytialvirus;PTLD,post-transplantlymphoproliferativedisease;aHLA(humanleucocyteantigen)typingforcordbloodunits–serologicforclassI;highresolutionforclassII,bHLAtypingforbonemarrowdonorHighresolutionforclassIandclassII;caGVHDwasgradedaccordingtoGlucksbergcriteria(Glucksbergetal,1974).
ª2007VandersonRocha
JournalCompilationª2007BlackwellPublishingLtd,BritishJournalofHaematology,137,248–251
249
Second transplant with two unrelated cord blood units for early graft failure after cord blood trans_临床医学_医药卫生_专业资料。Second transplant with two...
Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation. Br J Haematol 2007; 137: 248–...
unrelated donors and cord blood units, HSCT is no longer limited only to ...second transplant with conditioning due to graft failure, patients expired ...
unrelated donors and cord blood units, HSCT is no longer limited only to ...second transplant with conditioning due to graft failure, patients expired ...
热门文档